Pfizer seeking authorisation for 4th Covid dose for seniors: Report

Drugmaker Pfizer is expected to request authorisation this week for an additional Covid-19 booster dose for seniors, according to a person familiar with the matter.

Pfizer
A medical worker prepares to dilute a vial of Pfizer-BioNTech vaccine at a coronavirus disease vaccination center in Singapore (Photo: Reuters)
AP Washington
2 min read Last Updated : Mar 16 2022 | 8:16 AM IST

Drugmaker Pfizer is expected to request authorisation this week for an additional COVID-19 booster dose for seniors, according to a person familiar with the matter.

It would add a fourth dose to the regimen, which currently consists of a primary series of two shots, followed months later by a booster dose, in an effort to provide maximum protection to the over-65 population that has been hit hardest by the pandemic.

The Food and Drug Administration and the Centers for Disease Control must approve the request. The person who spoke about the upcoming Pfizer authorisation request spoke on condition of anonymity because the person wasn't authorized to speak on the record.

We're continuing to collect and assess all available data and we're in continuous, open dialogue with regulators and health authorities to help inform a COVID-19 vaccine strategy as the virus evolves, said Pfizer spokeswoman Jerica Pitts.

Speaking to CBS' Face the Nation on Sunday, Pfizer CEO Albert Bourla said, Right now, the way that we have seen, it is necessary, a fourth booster right now."

The protection that you are getting from the third, it is good enough, actually quite good for hospitalisations and deaths. It's not that good against infections, but doesn't last very long. But we are just submitting those data to the FDA and then we will see what the experts also will say outside Pfizer.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusPfizerCoronavirus Vaccine

First Published: Mar 16 2022 | 8:16 AM IST

Next Story